| Turkey | Austria | Spain | |
| Pancreas biopsy | from $1,000 | from $1,850 | from $1,200 |
No hidden fees – just official clinic prices. Pay at the clinic for Pancreas biopsy upon arrival and use a flexible installment plan if needed.
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Pancreas biopsy and have the necessary licenses to serve international patients worldwide.
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Pancreas biopsy journey.
Dr. Abdulcabbar Kartal is a certified Fellow of the European Board of Surgery. He treats complex gastrointestinal cancers at the JCI-accredited Anadolu Medical Center.
Professor Christoph Zielinski leads the International Oncology Center at Wiener Privatklinik. Diagnosis of pancreatic tumors and cancer immunotherapy are core focuses of his clinical practice.
Dr. Andreas Sesterhenn is the Chief Physician of Otolaryngology and Plastic Surgery at Solingen Clinic. He specializes in tumor removal for the head, neck, and upper airways. Dr. Sesterhenn uses robotic systems for interventions through incisions as small as 1 cm. Developed expertise in surgical medicine through training in the USA and Germany.
Chief physician and professor. Grade 1 Expert at the Cancer Center, West China Hospital, Sichuan University (ranked No. 2 in China). Completed a postdoctoral fellowship in interventional radiology at the Chinese PLA General Hospital. Leads multidisciplinary team (MDT) care for complex tumors. Expert in minimally invasive interventional oncology for liver, lung, and pancreatic cancers.
Accreditations: Council Member, WATA. Member of CACA and CMDA committees on intervention, ablation, radioactive seeds, and pain. In 2023, inaugural director member, Palliative Care Committee, Sichuan MDA. Editorial board member of the Chinese Journal of Interventional Imaging and Therapy. Editorial board member of the Chinese Journal of Pain Medicine.
Leads 2 provincial S&T projects and 2 NSFC projects. Has 40+ papers, with 30+ as first or corresponding author. Highest impact factor: 10.73. Hepatocellular carcinoma (HCC) cohort: TACE + lenvatinib vs TACE + sorafenib. OS 18.97 vs 10.77 months. PFS 10.6 vs 5.4 months. ORR 66.8% vs 33.3%.